Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

• by Masih Kameh Khosh, Sascha Wellenbrock, Daniel Kameh Khosh, Tobias Hirsch, Abbas Agaimy, Dan Mon O'Dey

• June 2, 2026

HPV-specific innovations and controversies in therapeutic strategies for HPV-associated oropharyngeal carcinoma

• by Yulun He, Jiaqi Tang, Yun Li, Yating Hu, Yaodong He, Xiaolong Zhang, Yanbing Yao, Jiale Wang, Kunyu Chen, Yuqi Wang, Huan Li, Jianhua Wei

• June 1, 2026

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

• by

• June 1, 2026

• 4 min

Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU

• by Charlotte Van Isterdael, Edurne Mugarza, Piret Fischer, Koen Debackere, Peter Vandenberghe, Silvia Martin Lluesma, Johan Van Eldere, Isabelle Huys

• June 2, 2026